Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?

Will GLP-1 Analogues and SGLT-2 Inhibitors Become New Game Changers for Diabetic Retinopathy?

Diabetic retinopathy (DR) is the most frequent microvascular complication of diabetes mellitus (DM), estimated to affect approximately one-third of the diabetic population, and the most common cause of preventable vision loss. The available treatment options focus on the late stages of this complica...

Full description

Bibliographic Details
Main Authors: Katarzyna Wołos-Kłosowicz, Wojciech Matuszewski, Joanna Rutkowska, Katarzyna Krankowska, Elżbieta Bandurska-Stankiewicz
Format: Article
Language:English
Published: MDPI AG 2022-10-01
Series:Journal of Clinical Medicine
Subjects:
diabetic retinopathy
glucagon-like peptide 1 receptor agonists
GLP-1 Ras
sodium-glucose cotransporter 2 inhibitors
SGLT-2 inhibitors
Online Access:https://www.mdpi.com/2077-0383/11/20/6183

Internet

https://www.mdpi.com/2077-0383/11/20/6183

Similar Items